Custom cleavable PEGylated lipid nanoparticle development for controlled PEG shedding, trigger-responsive surface remodeling, payload-compatible formulation, and functional intracellular delivery studies.
PEGylation can improve LNP dispersion, reduce nonspecific surface interactions, and support stable particle formation, but a persistent PEG layer may also limit cell interaction, ligand accessibility, and endosomal membrane contact. Cleavable PEGylated LNPs are designed to keep the protective PEG layer when it is useful and remove or reduce that shielding after a defined chemical, enzymatic, redox, oxidative, hypoxic, or time-dependent trigger.
BOC Sciences develops cleavable PEG-lipid structures and integrates them into PEGylated lipid nanoparticles for mRNA, siRNA, other nucleic acids, proteins, peptides, and selected small molecules. We compare linker chemistry, PEG molecular weight, lipid anchor, PEG density, cleavage rate, particle stability, payload retention, and functional delivery so that PEG shedding is treated as a measurable formulation variable rather than an assumed benefit.
Cleavable PEGylated Lipid Nanoparticle IllustrationOur service platform connects cleavable PEG-lipid chemistry with LNP formulation, trigger-response testing, surface characterization, and functional evaluation. Projects can start from a client's existing LNP composition, a selected linker concept, or a delivery problem such as excessive PEG shielding or premature PEG loss.
We design PEG-lipid conjugates in which the PEG chain, cleavable linker, spacer, and lipid anchor are selected as one functional structure.
Cleavable PEG-lipids are screened in the context of the complete LNP rather than optimized as isolated materials.
We determine whether PEG removal occurs under the intended trigger while remaining sufficiently limited under non-trigger conditions.
We track both chemical cleavage and the resulting change in nanoparticle surface properties.
PEG cleavage is only useful if the resulting surface transition improves the downstream delivery step that limits the project.
Cleavable linkers can introduce additional sensitivity during mixing, purification, storage, and incubation, so formulation and process conditions are evaluated together.
Acid-cleavable PEG-lipids contain acid-labile bonds between the PEG segment and the lipid anchor or intermediate spacer. These linkages remain relatively stable under near-neutral conditions but hydrolyze more rapidly as the environment becomes acidic, allowing the PEG layer to be reduced after exposure to acidic extracellular regions or endosomal compartments.
Reduction-cleavable PEG-lipids use bonds that can be broken under reducing conditions. Disulfide-containing structures are widely used because the linker can remain comparatively stable before cellular entry and then undergo thiol-disulfide exchange after exposure to a more reducing intracellular environment, resulting in PEG detachment from the particle surface.
Enzyme-cleavable PEG-lipids incorporate a substrate sequence between PEG and the lipid anchor. When the corresponding enzyme recognizes and cleaves this sequence, the PEG-containing segment is released and the underlying LNP surface becomes more accessible. Cleavage efficiency depends strongly on substrate sequence and surface accessibility.
Hydrolytically cleavable PEG-lipids contain bonds that gradually degrade in aqueous environments without requiring a specific biological trigger. The rate of PEG shedding can be adjusted through linker structure, neighboring chemical groups, steric accessibility, and the local formulation environment.
Time-programmed PEG-lipids are designed so that linker cleavage proceeds according to an intrinsic kinetic profile rather than depending primarily on a localized biological stimulus. By modifying linker structure and surrounding substituents, PEG shedding can be tuned to occur over a selected time window after formulation or exposure to physiological temperature.
ROS- and hypoxia-responsive PEG-lipids translate changes in the local redox or oxygen environment into cleavage of the PEG-containing surface structure. Oxidation-sensitive motifs can break or rearrange in the presence of elevated reactive oxygen species, while hypoxia-responsive linkers undergo reductive transformation under oxygen-deficient conditions.
Share your lipid composition, payload, target compartment, and the trigger available in your model. We can compare feasible linker chemistries and define the measurements needed to choose one.
Conventional PEG-lipids can provide useful steric stabilization, but persistent surface shielding can remain a barrier after the LNP reaches the stage where stronger cell or membrane interaction is needed. Cleavable PEGylation adds a controllable surface transition to this formulation strategy.
The PEG layer can support particle formation, colloidal stability, and reduced nonspecific interaction before activation. A cleavable linker then provides a route to reduce surface shielding later, avoiding the need to choose permanently between a highly PEGylated stable particle and a more interactive low-PEG particle.
Removing part of the PEG corona can increase exposure of the underlying lipid surface and reduce steric barriers to cell association. The benefit is formulation dependent, so cleavable and non-cleavable controls should be compared under matched conditions rather than assuming dePEGylation will automatically increase uptake.
PEG can partially mask receptor-binding ligands, charged lipids, peptides, or other functional surface components. Cleavable PEG architectures can be designed as an unmasking layer, exposing these elements after the trigger and supporting staged nanoparticle interactions.
Persistent PEG can interfere with the close membrane contact needed for productive intracellular release. Triggered dePEGylation may restore access to membrane-active LNP components and improve the transition from cellular uptake to cytosolic payload activity when PEG shielding is a limiting factor.
Cleavable PEG strategies can be adapted to multiple payload classes, but the appropriate PEG density, linker stability, trigger window, and functional endpoint depend on what the LNP carries. We design the PEG-shedding study together with payload loading and retention rather than treating surface chemistry separately.
| Payload Type | Cleavable PEG-LNP Development Focus | Request Information |
|---|---|---|
| mRNA and Reporter RNA | Development focuses on mRNA integrity, encapsulation, PEG density, trigger-dependent dePEGylation, endosomal escape, and protein-expression readouts. Our LNPs for mRNA delivery platform can be combined with cleavable PEG screening. | Inquiry |
| siRNA and Short Nucleic Acids | Suitable for studies linking PEG shedding to cellular uptake, cytosolic availability, and gene silencing. We compare dePEGylation kinetics with knockdown behavior using matched non-cleavable controls and relevant siRNA-LNP development strategies. | Inquiry |
| CRISPR-Related RNA and RNP Payloads | Projects can address co-loading or RNP encapsulation together with PEG shedding, particle stability, uptake, endosomal escape, and functional editing readouts. Surface remodeling is tuned to preserve sensitive payloads during the formulation and trigger steps. | Inquiry |
| Proteins and Peptides | Cleavable PEG-LNPs can be evaluated for protein or peptide payloads requiring temporary surface shielding followed by stronger cell or membrane interaction. Development considers payload stability, aggregation, loading method, PEG cleavage, and activity after release. | Inquiry |
| Small Molecules | For hydrophobic, amphiphilic, or ionizable small molecules, we evaluate drug-lipid compatibility, loading, leakage, PEG cleavage, particle remodeling, and release behavior. The goal is to distinguish PEG shedding from direct payload release and identify whether the two processes should be coupled. | Inquiry |
| Fluorescent and Tracking Payloads | Fluorescent payloads or labeled LNP components can support mechanistic studies of PEG cleavage, surface remodeling, cellular uptake, and intracellular localization. Dual-label strategies can help distinguish nanoparticle movement from PEG-lipid shedding. | Inquiry |
Share your payload class, current LNP composition, target trigger, and functional endpoint. BOC Sciences can design a PEG-shedding strategy around the actual delivery bottleneck.
Cleavable PEG systems add a second optimization problem to PEGylation: the surface must remain protected before the trigger but become sufficiently exposed afterward. We use paired chemical, particle, and functional measurements to identify where that transition is failing.
Premature PEG Cleavage During Formulation or Incubation
Acid-labile, hydrolytic, redox-sensitive, or oxidation-sensitive linkers may begin reacting before the intended trigger. We compare formulation buffers, pH, temperature, purification conditions, storage intervals, and trigger-free controls to identify the source of premature dePEGylation.
Insufficient PEG Removal Under Trigger Conditions
A chemically responsive linker may still cleave too slowly when buried within a dense PEG corona or tightly packed lipid surface. We adjust linker accessibility, spacer length, PEG density, anchor structure, trigger strength, and exposure time while directly measuring cleavage rather than inferring it from particle size alone.
Excessive Particle Destabilization After DePEGylation
Rapid PEG removal can expose hydrophobic or charged surfaces and promote aggregation. We compare partial versus more complete dePEGylation, rebalance helper lipids and cholesterol, and evaluate whether the selected candidate remains physically interpretable after the trigger.
Reduced Cellular Uptake Caused by Residual PEG Shielding
Incomplete cleavage, strongly retained PEG fragments, or excessive initial PEG density can leave the particle functionally shielded. We combine cleavage analysis with cell-association measurements to determine whether residual surface PEG is still limiting access.
Poor Endosomal Escape Despite Efficient PEG Cleavage
Successful dePEGylation does not guarantee cytosolic delivery. We compare uptake, intracellular localization, escape-related readouts, and payload activity to determine whether the remaining limitation comes from lipid composition, trafficking, or insufficient membrane interaction.
Loss of Payload Retention During Surface Remodeling
PEG cleavage can change particle packing and expose defects that increase cargo leakage. We monitor trigger-dependent payload retention and use payload retention testing to distinguish desired surface remodeling from unwanted particle disassembly.
Tell us where the formulation fails: premature cleavage, weak trigger response, aggregation, low uptake, poor escape, or payload leakage. We can design a focused troubleshooting matrix around that bottleneck.
Projects are organized around a defined PEG-shedding objective. We establish what must remain protected, what should become exposed, when the transition should occur, and which analytical and functional measurements are needed to prove that the design works.
We review the payload, current or proposed LNP composition, target cell model, expected trigger, desired cleavage location or time window, and the main performance problem. This defines whether the project needs rapid dePEGylation, partial PEG removal, ligand unmasking, improved membrane interaction, or a more gradual surface transition.
Candidate linker classes, PEG lengths, spacers, and lipid anchors are selected and prepared. We define non-cleavable controls and analytical methods for following linker conversion or PEG release. Early screening eliminates structures that cleave too rapidly under baseline conditions or fail to respond in the intended trigger window.
Selected PEG-lipids are incorporated into matched LNP formulations while PEG fraction, core lipid composition, mixing conditions, purification, and buffer conditions are screened. Particle size, PDI, payload encapsulation, and baseline stability are compared before trigger testing so cleavage effects can be separated from formulation defects.
Lead candidates are challenged under trigger and non-trigger conditions, then evaluated for PEG loss, surface-property changes, payload retention, uptake, intracellular localization, and payload-specific activity. Results are organized into a comparative dataset that identifies the most useful linker/formulation combination and the next optimization direction.
Cleavable PEG-LNPs are most useful when a project needs different surface properties at different stages of delivery. The specific linker and cleavage window should therefore be chosen around the intended biological transition rather than treated as a universal formulation upgrade.
Challenge: A research group had an mRNA-LNP with an 85 nm diameter, PDI near 0.12, and over 90% encapsulation, but reporter expression remained low. Reducing PEG-lipid from 1.5 to 0.5 mol% slightly improved uptake but caused larger particles, aggregation, and poorer reproducibility. The team needed PEG-associated stability without persistent surface shielding.
Diagnosis: BOC Sciences found that cellular association was acceptable while reporter expression and endosomal escape remained weak. Persistent PEG was limiting post-uptake membrane interaction, whereas simply reducing PEG sacrificed formulation stability.
Solution: We screened hydrazone, acetal, orthoester, and vinyl ether PEG-lipids at 0.5-1.5 mol% with C14 and C18 anchors. PEG shedding was measured by FRET and cleavage confirmed by 1H NMR. Candidates were compared at pH 7.4, 6.0, and 5.5 for stability, shedding, reporter expression, lysosomal localization, and particle properties, with support from LNP transfection troubleshooting services.
Result: Seven candidates showed over 60% PEG release within 2 h at pH 6.0 while retaining more than 90% PEG during refrigerated storage at pH 7.4. The selected 1.5 mol% hydrazone PEG-lipid with a C18 anchor maintained a diameter near 90 nm and produced about 3.5-fold higher reporter expression than the non-cleavable control.
Challenge: A team developing a protease-responsive siRNA-LNP found that a 2.5 mol% PEG corona masked its targeting peptide. Lower PEG improved cell association but increased particle size above 150 nm and did not sufficiently improve knockdown. The goal was to retain shielding initially and expose the ligand only after protease activation.
Diagnosis: BOC Sciences found that part of the PEG-lipid was lost through anchor desorption rather than intended cleavage. After protease exposure, residual PEG also remained high enough to restrict ligand-receptor interaction.
Solution: We compared matrix metalloproteinase-responsive, cathepsin B-cleavable, and scrambled peptide-linker PEG-lipids at two PEG levels and three ligand densities. Cleavage, PEG retention, uptake, and gene silencing were evaluated using enzyme-treated and control conditions. Tissue distribution was further examined through nanoparticle in vivo distribution analysis.
Result: The matrix metalloproteinase-responsive linker at 1.5 mol% provided the best balance, releasing about 65% of PEG within 4 h while the scrambled control released below 10%. Cell association increased about 2.8-fold, target mRNA knockdown reached about 75%, and particle diameter remained near 100 nm.
Rapid Project Response and Customized Development PlanningWe quickly translate your payload, trigger, existing formulation, and performance bottleneck into a focused development plan with clear comparison groups, analytical readouts, and decision points.
Extensive PEG-Lipid, Linker, and Formulation Material OptionsProjects can draw from multiple PEG architectures, lipid anchors, linker classes, helper lipids, ionizable lipids, and payload-compatible formulation materials, with custom synthesis used when a suitable cleavable PEG-lipid is not already available.
Experienced Scientists in PEG-Lipid and LNP DevelopmentOur scientists evaluate cleavable PEG chemistry together with nanoparticle assembly, surface behavior, payload retention, intracellular trafficking, and functional delivery so that design decisions reflect the complete LNP system.
Documented Workflows and Clear Experimental RecordsExperimental conditions, formulation variables, trigger settings, analytical methods, and comparison results are organized into clear project records that help research teams understand why a candidate was selected and what should be tested next.
End-to-End Support from Molecular Design to Functional EvaluationBOC Sciences can support the full sequence from cleavable linker and PEG-lipid design through LNP formulation, physicochemical characterization, trigger-response testing, cellular evaluation, troubleshooting, and lead-candidate comparison.
Cleavable PEGylated lipid nanoparticles contain a responsive or degradable linker between the PEG segment and the lipid anchor. The PEG corona can provide steric protection during particle formation, dispersion, and early transport, then partially detach under acidic, reducing, enzymatic, oxidative, hypoxic, or time-dependent conditions. Unlike permanently PEGylated LNPs, these systems are designed to create a controlled transition between surface shielding and increased surface accessibility. The goal is not simply to reduce PEG content, but to preserve useful stability first and then improve ligand exposure, cellular interaction, or membrane contact when needed.
Linker selection should begin with where and when PEG shedding is expected to occur. Acid-labile linkers can support pH-dependent dePEGylation, disulfides respond to reducing environments, peptide linkers enable enzyme-dependent cleavage, and ester or carbonate linkers can provide gradual hydrolysis. Kinetically programmed linkers may also be useful when predictable time-dependent shedding is preferred. BOC Sciences can compare linker chemistry together with PEG molecular weight, lipid anchor, spacer design, payload type, and desired cleavage window, allowing multiple PEG-lipid candidates to be screened within the same LNP formulation framework.
No. Very rapid PEG loss may reduce colloidal stability, increase aggregation, expose highly interactive lipid surfaces too early, or promote payload leakage. In contrast, excessively slow cleavage may leave the particle persistently shielded and limit ligand accessibility, cellular uptake, or endosomal membrane interaction. The preferred design therefore depends on achieving an appropriate cleavage window rather than maximizing the rate. BOC Sciences can compare triggered and non-triggered conditions while monitoring PEG retention, particle size, PDI, payload retention, uptake, endosomal escape, and functional delivery to determine whether the shedding profile is appropriately balanced.
Changes in particle size or zeta potential alone do not reliably prove PEG cleavage because similar changes can result from aggregation, lipid rearrangement, or spontaneous PEG-lipid desorption. More direct approaches measure intact PEG-lipid, released PEG-containing fragments, or cleavage products using suitable chromatographic, mass spectrometric, NMR, fluorescence, or FRET-based methods. BOC Sciences can combine these measurements with particle characterization, payload-retention analysis, and functional testing before and after the trigger. This helps distinguish designed linker cleavage from ordinary anchor desorption or nonspecific particle destabilization.
Cleavable PEGylated LNPs can be developed for mRNA, siRNA, other short nucleic acids, CRISPR-related RNA or ribonucleoprotein payloads, proteins, peptides, selected small molecules, and fluorescent or imaging cargos. The preferred PEG density, linker chemistry, and shedding profile depend strongly on the payload. RNA systems often emphasize encapsulation, endosomal escape, and functional expression, while protein or peptide systems may require additional attention to aggregation and retained activity. Small-molecule formulations may also need to separate PEG shedding from payload release. For this reason, surface remodeling should be optimized together with loading, retention, and payload-specific functional readouts.
